Impact of recent innovations in the use of mass cytometry in support of drug development

Nassar, Ala F.; Ogura, Hideki; Wisnewski, Adam V.

doi:10.1016/j.drudis.2015.06.001

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Impact of recent innovations in the use of mass cytometry in support of drug development

Published Date:

Jun 16 2015

Publisher's site:

http://dx.doi.org/10.1016/j.drudis.2015.06.001 New Site Icon

Source:

Drug Discov Today. 20(10):1169-1175.

[PDF-329.87 KB]

Details:

Personal Authors:

Nassar, Ala F. ; Ogura, Hideki ; Wisnewski, Adam V. ;

Keywords:

[+]

Pubmed ID:

26092491

Pubmed Central ID:

PMC4668584

Description:

Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which maximizes the information obtained from each individual sample. CyTOF provides the ability to phenotypically and functionally profile cells from normal and diseased states. Single cell technologies enable researchers to measure the effects of a drug at the single cell level and better understand its mechanism of action. Here, we discuss novel instruments for the analysis of individual biological cells, the impact of recent innovations in support of drug development, and the important roles of CyTOF in drug profiling.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

R21 OH010438/OH/NIOSH CDC HHS/United States
R21 OH010494/OH/NIOSH CDC HHS/United States

Supporting Files:

	nihms740874.nxml	application/octet-stream
	nihms740874f1.gif	image/gif
	nihms740874f1.jpg	image/jpeg
	nihms740874f2.gif	image/gif
	nihms740874f2.jpg	image/jpeg
	nihms740874f3.gif	image/gif
	nihms740874f3.jpg	image/jpeg

No Related Documents.

You May Also Like:

Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization

Personal Author:

Nassar, Ala F.; Wisnewski, Adam V.; Raddassi, Khadir;

Published:

Jan 26 2017

Source:

Anal Bioanal Chem. 409(9):2363-2372.

Description:

Analysis of multiplexed assays is highly important for clinical diagnostics and other analytical applications. Mass cytometry enables multi-dimensional, single-cell analysis of cell type and state. In mass cytometry, the rare earth metals used as rep...

File Type:

[PDF - 2.08 MB]
Shifting the HIV Paradigm from Care to Cure: Proceedings from the Caribbean Expert Summit in Barbados, August 2017

Personal Author:

Landis, R. Clive; Abayomi, E. Akinola; Bain, Brendan C.; Greene, Edward; Janossy, George; Joseph, Patrice; Kerrigan, Deanna; McCoy, J. Philip; Nunez, Cesar; O'Gorman, Maurice; Pastoors, Alexander; Parekh, Bharat S.; Quimby, Kim R.; Quinn, Thomas C.; Robertson, Kevin R.; Thomas, Réjean; van Gorp, Eric; Vermund, Sten H.; Wilson, Valerie;

Published:

Jun 05 2018

Source:

AIDS Res Hum Retroviruses. 2018; 34(7):561-569.

Description:

The CCAS EXPERT SUMMIT convened an array of international experts in Barbados on August 27-31, 2017 under the theme "From Care to Cure-Shifting the HIV Paradigm." The Caribbean Cytometry & Analytical Society (CCAS) partnered with the Joint United Nat...

File Type:

[PDF - 220.09 KB]
Effect of mucosal cytokine administration on selective expansion of vaginal dendritic cells to support nanoparticle transport

Personal Author:

Ramanathan, R.; Park, J.; Hughes, S.M.; Lykins, W.R.; Bennett, H.R.; Hladik, F.; Woodrow, K.A.;

Published:

Jun 27 2015

Source:

Am J Reprod Immunol. 74(4):333-344.

Description:

Problem : The capacity of antigen-carrying vaccine nanoparticles administered vaginally to stimulate local immune responses may be limited by the relatively low numbers of antigen-presenting cells (APCs) in the genital mucosa. Because inflammation is...

File Type:

[PDF - 1.11 MB]
Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide

Personal Author:

McFaline-Figueroa, José L.; Braun, Christian J.; Stanciu, Monica; Nagel, Zachary D.; Mazzucato, Patrizia; Sangaraju, Dewakar; Cerniauskas, Edvinas; Barford, Kelly; Vargas, Amanda; Chen, Yimin; Tretyakova, Natalia; Lees, Jacqueline A.; Hemann, Michael T.; White, Forest M.; Samson, Leona D.;

Published:

May 29 2015

Source:

Cancer Res. 75(15):3127-3138.

Description:

Glioblastoma (GBM) is often treated with the cytotoxic drug temozolomide, but the disease inevitably recurs in a drug-resistant form after initial treatment. Here, we report that in GBM cells, even a modest decrease in the mismatch repair (MMR) compo...

File Type:

[PDF - 1.70 MB]
Biological frontiers in multiple myeloma: From biomarker identification to clinical practice

Personal Author:

Landgren, Ola; Morgan, Gareth J.;

Published:

Nov 22 2013

Source:

Clin Cancer Res. 20(4):804-813.

Description:

Since the mid-1990s, the multiple myeloma treatment landscape has evolved considerably, which has led to improved patient outcomes and prolonged survival. In addition to discovering new, targeted agents or treatment regimens, the identification and v...

File Type:

[PDF - 420.37 KB]